Internal Medicine Department, University Hospitals Seidman Cancer Center , Cleveland , OH , USA.
Stem Cell Transplant Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center and Case Western Reserve University , Cleveland , OH , USA.
Leuk Lymphoma. 2019 Sep;60(9):2199-2206. doi: 10.1080/10428194.2019.1573367. Epub 2019 Mar 7.
Lenalidomide (LEN) is commonly used as part of induction therapy in transplant-eligible patients with multiple myeloma. However, LEN use is associated with increased chance of peripheral blood stem cell (PBSC) collection failure. This has led to early collection in patients receiving induction with LEN-containing regimens, and the use of mobilization agents such as plerixafor. Despite potential significant clinical implications, the impact of LEN on autograft composition is unclear. We examined the effect of LEN exposure on hematopoietic progenitors in collected grafts of 94 patients who underwent autologous stem cell transplantation (HSCT) at our institution. LEN exposure resulted in lower myeloid and erythroid progenitors in collected grafts, but this effect was not seen in patients who received plerixafor-based mobilization. Exposure to LEN did not affect PBSC collection, possibly due to high plerixafor use in our cohort (70%). LEN changes the composition of PBSC grafts; the clinical implication of this finding is unknown.
来那度胺（LEN）常用于有移植资格的多发性骨髓瘤患者的诱导治疗中。然而，LEN 的使用与外周血干细胞（PBSC）采集失败的几率增加有关。这导致了接受 LEN 含药方案诱导的患者提前采集，以及使用动员剂，如培非格司亭。尽管有潜在的重要临床意义，但 LEN 对自体移植成分的影响尚不清楚。我们研究了 LEN 暴露对 94 例在我院接受自体干细胞移植（HSCT）患者采集的移植物中造血祖细胞的影响。LEN 暴露导致采集的移植物中髓系和红系祖细胞减少，但在接受培非格司亭动员的患者中未观察到这种作用。LEN 暴露不影响 PBSC 采集，可能是因为我们组培非格司亭的使用率很高（70%）。LEN 改变了 PBSC 移植物的组成；这一发现的临床意义尚不清楚。
